Latest News and Press Releases

Findings highlight the unmet medical need among cancer patients with BRAF Class II and Class III alterations who may not have access to approved targeted therapies SAN FRANCISCO and SAN DIEGO, March ...

SAN FRANCISCO and SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...

SAN FRANCISCO and SAN DIEGO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...

SAN FRANCISCO and SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...

SAN FRANCISCO and SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...

SAN FRANCISCO and SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...

Announces proof-of-concept preclinical data demonstrating activity of KIN-2787 in NRAS-mutant melanoma Provides update on ongoing KN-8701 trial with expansion to include patients with NRAS-mutant...

AACR Special Conference: Targeting RAS presentation will highlight findings from real-world clinico-genomic study collaboration with Tempus investigating prevalence of Class II and Class III BRAF...

SAN FRANCISCO and SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...

In collaboration with Guardant Health, announced initial findings from BRAF Kinase Alteration Genomic Landscape and Real-World Clinical Outcomes Study Ended the quarter with cash, cash equivalents...